Solara Pharma Stocks Mein Tezi: Kya Hai Update?
Solara Active Pharma Sciences ke stocks mein ek dum se tezi aayi hai! Pichle ek mahine mein, company ke shares 34% tak badh gaye hain. Investors ka confidence badh raha hai, aur iski wajah hai company ka naya plan. Chaliye dekhte hain kya hai yeh naya update.
Company Ka Naya Plan Kya Hai?
Solara ab lower-margin markets se door hokar higher-value markets par focus kar rahi hai. Iska matlab hai ki ab company ka dhyan regulated global markets par hoga. Already, company ke total business mein 76% hissa regulated markets ka hai. Iske saath hi, Solara plain Ibuprofen drug par apni dependency kam kar rahi hai aur value-added Ibuprofen derivatives aur non-Ibuprofen products par focus kar rahi hai.
Solara Ka Core Business Kya Hai?
Solara Active Pharma Sciences APIs banati hai, jo ki drugs banane mein use hote hain. Company ke paas 60 se zyada commercial APIs hain, jismein anti-inflammatory aur anti-infective segments ke products bhi shamil hain. Solara Ibuprofen ki ek badi global supplier hai aur Contract Research and Manufacturing Services (CRAMS) bhi offer karti hai.
CRAMS & Polymers Demerger: Future Plan
Solara apne CRAMS aur Polymers businesses ko ek naya independent entity banane ja rahi hai, jiska naam Synthix Global Pharma Solutions hoga. Isse company ko focused growth mein madad milegi. Nayi CRAMS entity, jiska revenue currently Rs 100 crore hai, mein 1000 KL capacity hai. Synthix Global Pharma Solutions complex drug contract manufacturing mein specialize karegi aur iska turnover agle 3-4 saalon mein Rs 500 crore tak pahunchne ki umeed hai.
FY25: Challenges Aur Comeback
Fiscal year 2025 Solara ke liye mushkil raha, kyunki Ibuprofen market mein challenges the. Lekin, company ne financial metrics mein sudhar dikhaya hai. FY22 se FY25 ke beech, Gross Margin 37.8% se badhkar 51.5% ho gaya, aur EBITDA Margin bhi negative se sudhar kar 16.5% ho gaya.
Balance Sheet Ko Strong Karna
Solara apne financial health ko improve karne ke liye debt kam karne par focus kar rahi hai. Gross debt FY24 mein Rs 1,000 crore se kam hokar Rs 776 crore ho gaya hai. Company ka target hai ki Q1 FY27 tak net debt/EBITDA ko 1.7–1.8x tak le aaye aur debt-free entity ban jaye.
FY26 Ke Liye Outlook
Solara Active Pharma Sciences FY26 ke liye strong performance ki umeed kar rahi hai. Company ko revenue mein 10% aur EBITDA mein 15–20% growth ki umeed hai. Is positive outlook ki wajah gross margin expansion aur operational efficiencies hain.
